BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GLPG0259: Phase II discontinued

Galapagos discontinued a double-blind, placebo-controlled, international Phase II trial of GLPG0259 after an analysis by an interim review committee showed "limited efficacy potential" of the compound. The committee analyzed unblinded safety and efficacy data from the first 30 patients enrolled in the trial. No serious adverse events or safety signals were reported. The...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >